(Q37088460)

18 August 2017

1 reference

title

Sunitinib therapy in renal cell carcinoma (English)

1 reference

18 August 2017

3

Robert J Motzer

1 reference

18 August 2017

Matthew F O'Brien

1

1 reference

18 August 2017

Paul Russo

series ordinal

2

1 reference

18 August 2017

publication date

18 February 2008

1 reference

18 August 2017

1 reference

18 August 2017

volume

101

1 reference

18 August 2017

issue

11

1 reference

18 August 2017

page(s)

1339-1342

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07506.X

18 August 2017

1 reference

Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07506.X

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07506.X

Identification of the von Hippel-Lindau disease tumor suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07506.X

Role of VHL gene mutation in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07506.X

The von Hippel-Lindau tumor suppressor gene and kidney cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07506.X

Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07506.X

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07506.X

Sunitinib in patients with metastatic renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07506.X

Sunitinib efficacy against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07506.X

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07506.X

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07506.X

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07506.X

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07506.X

Phase III study of interferon alfa-NL as adjuvant treatment for resectable renal cell carcinoma: an Eastern Cooperative Oncology Group/Intergroup trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07506.X

Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07506.X

Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2008.07506.X

10.1111/J.1464-410X.2008.07506.X

21 January 2018

Identifiers

DOI

1 reference

18 August 2017

1 reference